HAI-ROBOTICS
27.12.2021 10:09:04 CET | Business Wire | Press release
HAI ROBOTICS , a global leader in Autonomous Case-handling Robotics (ACR) systems for warehouse order fulfillment, is celebrating its fifth anniversary at its new headquarters as it ranks among global unicorns according to this year’s unicorn ranking list from the Hurun Research Institute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211226005013/en/
The company, a logistics warehousing automation solution provider that secured three rounds of funding in 2021, was nominated along with 300 other Chinese start-ups which were valued at more than US$1 billion as of November this year in a global list totaling 1,058. The list was released last week.
HAI ROBOTICS was founded in late 2016 by a group of like-minded robot enthusiasts who aspire to create value for every warehouse and factory with the vision to push forward human civilization through robotics technology. The company’s birth originated from a revolutionary idea that took shape as early as 2015 – the totes-to-person solution – to improve warehouse operational efficiency, instead of creating a homogenous brand of the then prevalent shelves-to-person material handling.
The solution underwent repeated tests and trials in a real warehouse environment for nearly two years before it was formally introduced into the market. The company’s first project was successfully deployed in Best Logistics’ warehouse in August 2018. Soon the story went viral with great exemplary effect that the ACR solution swiftly secured footholds in factories and warehouses.
“It’s an extraordinary journey for us to grow from the cradle of a small workshop into a company of more than 1,200 employees with five branch offices across the globe today,” said Richie Chen, the company’s founder and CEO. “We’re celebrating our fifth anniversary with gratitude to our customers and investors for their trust and confidence in our team. We’ll keep making innovative products and stay committed to bringing value to our partners.”
Automating a warehouse can be a huge project worthy of careful consideration for any business operator. The concerns could range from the length of necessary deployment time, agility of refitting, affordability to ROIs. The HAI ROBOTICS team kept their users’ concerns in mind when building their products. Hence, they kept refining their ideas and fine-tuning the HAIPICK robots for wider applications and stricter storage requirements.
First and foremost, the HAIPICK ACR solution allows greater space utilization and higher goods-handling precision and efficiency than traditional Goods-to-Person solutions, such as Kiva robots that move an entire rack. With the HAIPICK ACR solution, a warehouse’s storage density can be boosted by 80% to 400% and a worker’s picking speed can be improved 3 to 4 times. In addition, the HAIPICK robots, using QR codes on the floor for navigation, can be deployed within one month with no altering of the interior structure of a warehouse.
Thanks to its easy deployment and flexibility, the solution has been adopted by a wide array of customers who prefer smaller picking units than an entire rack or pallet when automating their warehouses. So far, HAI ROBOTICS has been running more than 300 projects globally in various fields, including e-commerce, 3PL, apparel, electronics, energy, manufacturing, medicine, and more. To provide localized service overseas, it has partnered with dozens of global logistics and supply chain leaders, including LG CNS, MHS, MUJIN, BPS, Savoye, Invar, SSI Schaefer and more.
About HAI ROBOTICS
HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse.
The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 with headquarters in Shenzhen, China, HAI ROBOTICS has set up five subsidiaries in Hong Kong SAR, Japan, Singapore, the U.S. and the Netherlands, serving customers from more than 30 countries and regions. It now has over 1,200 staff, more than 50% of whom are engineers. The company has acquired more than 600 global patents for core intellectual properties involving positioning, robot control and warehouse management. In the latest C and D rounds of funding in 2021, the company raised over US$200 million in total.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211226005013/en/
Link:
Social Media:
https://www.facebook.com/HAIROBOTICS/videos/?ref=page_internal
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
